Drug profile · INN
filgrastim
NIVESTIM
filgrastim (NIVESTIM) is a granulocyte colony stimulating factor receptor agonist. Associated with Pfizer Australia Pty Ltd. Current US regulatory status: approved.
Drug details — filgrastim
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L03)
- Route
- —
- Patents
- 0
- Programs
- 36
- Data quality
- 0.89
Quick answer
filgrastim (NIVESTIM) is a granulocyte colony stimulating factor receptor agonist. Associated with Pfizer Australia Pty Ltd. Current US regulatory status: approved.
Key facts
Mechanism of action
Granulocyte colony stimulating factor receptor agonist
Primary target: Granulocyte colony-stimulating factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is filgrastim?
filgrastim (NIVESTIM) is a granulocyte colony stimulating factor receptor agonist. Associated with Pfizer Australia Pty Ltd. Current US regulatory status: approved.
What is the brand name for filgrastim?
NIVESTIM is a marketed brand name for filgrastim. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of filgrastim?
filgrastim has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.